Výsledky vyhledávání

MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma

Autor: Michelle Tighe Nestor, Youlan Rao, Denise L. Driscoll, Kerri Lasky, Matt O. Duffey, Debra Liao, Mark G. Qian, Natalie D' Amore, Mark Manfredi, Bradley Stringer, Vaishali Shinde, Marc Hyer, Judy Shi, Benjamin S. Amidon, Raymond W. Liu, Tricia J. Vos

Publikováno v: Molecular cancer therapeutics. 11(9)

Diffuse large B-cell lymphoma (DLBCL) is the most common of the non–Hodgkin lymphomas, accounting for up to 30% of all newly diagnosed lymphoma cases. Current treatment options for this disease are effective, but not always curative; therefore, exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd66f3095dc45048c4d8da651133f01
https://pubmed.ncbi.nlm.nih.gov/22609854

Zobrazit plný text záznamu

Using preclinical PD/E correlations to derive an optimal PD threshold for phase-1 decision-making

Autor: Andrew Chen, Yuko Ishii, Jeffrey Ecsedy, Dean Bottino, Jing-Tao Wu, Ekta Kadakia, Arijit Chakravarty, Cindy Q. Xia, Munjal Patel, Marc Hyer

Publikováno v: Journal of Clinical Oncology. 33:e13579-e13579

e13579 Background: During phase-1 oncology trials, early pharmacodynamic (PD) signals are often interpreted as predicting later outcomes of antitumor activity (E). A major complication in making th...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65fa15c327612281c07ab7100dda0ac3
https://doi.org/10.1200/jco.2015.33.15_suppl.e13579

Zobrazit plný text záznamu

cIAP1 Localizes to the nuclear compartment and modulates the cell cycle

Autor: Temesgen Samuel, Kazuya Okada, Marc Hyer, Kate Welsh, Juan M. Zapata, John C. Reed

Publikováno v: Cancer research. 65(1)

We explored the location and function of the human cIAP1 protein, a member of the inhibitor of apoptosis protein (IAP) family. Unlike family member X-linked IAP (XIAP), which was predominantly cytoplasmic, the cIAP1 protein localized almost exclusive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f0c1b8dc2b8354952b9ab2c68b8fbb0
https://pubmed.ncbi.nlm.nih.gov/15665297

Zobrazit plný text záznamu

Abstract 4153: Arrayed microinjection of a ubiquitin activating enzyme inhibitor induces PD biomarker effects predictive of in vivo tumor responses to systemic drug delivery

Autor: Nathan Hedin, Richard A. Klinghoffer, Neil Bence, Beryl A. Hatton, Stephen J. Blakemore, Mark Manfredi, Nathan Caffo, Marc Grenley, Marc Hyer

Publikováno v: Cancer Research. 73:4153-4153

Presage technology enables simultaneous analysis of multiple cancer drug candidates, drug concentrations, and drug combinations within a single living tumor. The platform employs arrayed tumor microinjection technology that delivers multiple spatiall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a32ac7b2e5073ca2d4fb959ebe023f56
https://doi.org/10.1158/1538-7445.am2013-4153

Zobrazit plný text záznamu

The Investigational Aurora A Kinase Inhibitor MLN8237 in Combination with Vincristine Demonstrates Robust Anti-Tumor Activity in Preclinical B-Cell Non-Hodgkin's Lymphoma Models

Autor: Wen Chyi Shyu, Susan Chen, Karuppian Kannan, Jeffrey Ecsedy, Mark Manfredi, Mengkun Zhang, Jessica Huck, Marc Hyer

Publikováno v: Blood. 118:2733-2733

Abstract 2733 Aurora A kinase (AAK) is a serine/threonine protein kinase that is essential for normal mitotic progression. MLN8237, an investigational, selective inhibitor of AAK, is being evaluated in multiple Phase 1 and 2 clinical studies in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a76abc593db585bca659708575331594
https://doi.org/10.1182/blood.v118.21.2733.2733

Zobrazit plný text záznamu

Abstract C82: Identification and preclinical characterization of inhibitors of the ubiquitin-activating enzymes UBA1 and UBA6

Autor: Paul E. Fleming, James M. Gavin, Yu Yang, Marc Hyer, Petter Veiby, Michael Milhollen, Peter G. Smith, Tary Traore, Sai M. Pulukuri, Jeff Ciavarri, Mark Manfredi, Darshan S. Sappal, Neil Bence, James E. Brownell, Kara Hoar, Jessica Huck, Christopher F. Claiborne, Lawrence Dick, Derek Liqiang Tou

Publikováno v: Molecular Cancer Therapeutics. 10:C82-C82

Millennium Pharmaceuticals, Inc. is dedicated to the discovery and development of novel oncology therapeutics in the area of protein homeostasis. Here we report the identification and characterization of compounds that target the ubiquitin activating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf46ab98094e19a549c2b41c70c866cd
https://doi.org/10.1158/1535-7163.targ-11-c82

Zobrazit plný text záznamu

Abstract 3573: A small molecule PLK1 inhibitor, MLN0905, yields broad anti-tumor activity in human xenograft tumor models, and synergizes with taxane therapy

Autor: Mark G. Qian, Matthew O. Duffey, Natalie D'Amore, Vaishali Shinde, Youlan Rao, Raymond W. Liu, Judy Shi, Debra Liao, Kerri Lasky, Bradley Stringer, Tricia J. Vos, Marc Hyer

Publikováno v: Cancer Research. 71:3573-3573

PLK1 is a serine/threonine mitotic kinase that plays a key role in mitotic cell cycle progression, and its over-expression has been linked to poor patient prognosis. We have discovered a potent and selective small molecule inhibitor of PLK1, MLN0905,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b592dc5ca35f628b12c8db400db1c40a
https://doi.org/10.1158/1538-7445.am2011-3573

Zobrazit plný text záznamu

A Small Molecule PLK1 Inhibitor, MLN0905, Induces An Anti-Tumor Response In Human Models of Diffuse Large B-Cell Lymphoma

Autor: Kerri Lasky, Vashali Shinde, Matt O. Duffey, Mark G. Qian, Judy Shi, Debra Liao, Raymond W. Liu, Youlan Rao, Tricia J. Vos, Marc Hyer, Natalie D'Amore, Bradley Stringer

Publikováno v: Blood. 116:3922-3922

Abstract 3922 Diffuse large B-cell lymphoma (DLBCL) is the most common of the non-Hodgkin lymphomas, accounting for up to 30 percent of newly diagnosed cases. Current treatment options for this disease are effective, but not always curative; therefor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32a5b5cb7362ec27b0edfcc2dd27e212
https://doi.org/10.1182/blood.v116.21.3922.3922

Zobrazit plný text záznamu

Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models

Autor: Marc Hyer, Jessica Huck, Mark Manfredi, Jeffrey Ecsedy, Mengkun Zhang

Publikováno v: Journal of Clinical Oncology. 27:8553-8553

8553 Background: Aurora A kinase is a serine/threonine protein kinase that is essential for the successful transit of cells through mitosis. MLN8237 is a selective small molecule inhibitor of Aurora A kinase that has demonstrated anti-tumor activity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df8d751b0fdae14fad4eecccb2037047
https://doi.org/10.1200/jco.2009.27.15_suppl.8553

Zobrazit plný text záznamu

Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models

Autor: Mark Manfredi, Mengkun Zhang, Jessica Huck, Marc Hyer

Publikováno v: Blood. 112:1592-1592

Aurora A kinase is a serine/threonine protein kinase that is essential for normal transit of cells through mitosis. In many tumor types the Aurora A gene is amplified and/or the protein is over-expressed. The Aurora A small-molecule inhibitor MLN8237

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e76c477748c23a22d83d3330bc53d91d
https://doi.org/10.1182/blood.v112.11.1592.1592

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání